Oncology · AntiemeticRegulatory Approvalregulatorymid-term

FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/6/2026, 6:00:36 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's receipt of a supplemental application for Ondansetron Hydrochloride indicates potential changes in the competitive landscape for antiemetic therapies. This could lead to new formulations or indications that may affect market dynamics. Regulatory context from FDA (FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 24 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry and competitive positioning of PHARM ASSOC.'s product. The strongest clinical anchor is Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Antiemetic, 8 regulatory and 3 competitive items passed relevance filtering for PHARM ASSOC..

Competitive Pressure

The most relevant competitive pressure comes from FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA Issues Guidance on Postapproval Pregnancy Safety Studies. This submission may impact the market for ondansetron products, particularly if it leads to new formulations or indications.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL) (FDA). Entity match (pharm assoc ); Regulatory pathway relevance (nda). The approval process for this supplemental application could lead to new regulatory pathways or label changes for ondansetron products, influencing compliance requirements.

Key Risks

Elevated medium regulatory exposure for PHARM ASSOC. could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, PHARM ASSOC.'s product could capture market share from existing ondansetron products, impacting revenue for competitors.
Upside for PHARM ASSOC. may improve if Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for PHARM ASSOC. may improve if Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone. (PubMed) delivers favorable follow-through.
Oncology · HER2-positive solid tumours · Regulatory Approval · If approved, Enhertu will be the first HER2-directed therapy with a tumour agnostic indication in the EU, potentially setting a new standard in treatment.
Portfolio teams should assess the potential market entry and competitive positioning of PHARM ASSOC.'s product.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review process and any subsequent approvals or market entries related to this application.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (pharm assoc ); Regulatory pathway relevance (nda)
FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Entity match (ondansetron hydrochloride); Regulatory pathway relevance (nda)
FDA AP — LEVOCETIRIZINE DIHYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)

Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury
ClinicalTrials.govmedium relevance
Moderate corpus alignment
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
Non-Pharmacological Methods in Heel Lance
ClinicalTrials.govmedium relevance
Moderate corpus alignment
Diagnosis, Determining Factors, and Characteristics of Pathologies Associated With Autoinflammatory Diseases.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
ClinicalTrials.govmedium relevance
Moderate corpus alignment
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment

FDA Submission for Dapagliflozin by Jiangsu Hansoh Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Issues Guidance on Postapproval Pregnancy Safety Studies
Humanexa Signalsmedium relevance
Moderate corpus alignment
Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.
PubMedmedium relevance
Moderate corpus alignment
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leuke
PubMedmedium relevance
Moderate corpus alignment
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

PHARM ASSOC.
Ondansetron Hydrochloride
ondansetron products market

Commercial impact

medium

If approved, PHARM ASSOC.'s product could capture market share from existing ondansetron products, impacting revenue for competitors.

Regulatory impact

medium

The approval process for this supplemental application could lead to new regulatory pathways or label changes for ondansetron products, influencing compliance requirements.

What to watch

Monitor the FDA's review process and any subsequent approvals or market entries related to this application.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.